Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)
While typesetting the articles the formatting of the Tables was incorrect. Now this has been corrected. The original article has been corrected.
Saved in:
Main Author: | Popat S. |
---|---|
Other Authors: | Mahidol University |
Format: | Erratum |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/81644 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
by: Popat S.
Published: (2023) -
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020) -
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020) -
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Tan, Wan-Ling, et al.
Published: (2022) -
Correction to: Noninvasive respiratory support in intensive care medicine (Intensive Care Medicine, (2022), 48, 9, (1211-1214), 10.1007/s00134-022-06762-6)
by: Rittayamai N.
Published: (2023)